Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
- Sponsor
- Zhejiang Provincial People's Hospital
- Study ID
- NCT07491016
- Status
- Recruiting
Conditions
- Rheumatoid Arthritis
- Telitacicept
- Treatment Compliance
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Study Details
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients
Key Dates
- First listed
- Mar 24, 2026
- Start date
- Mar 1, 2026
- Status verified
- Mar 2026
- Primary completion
- Mar 30, 2027
- Completion
- Mar 30, 2028
Study Design
- Enrollment
- 30 participants (estimated)
Arms
- Arm: Telitacicept; Baricitinib. One group of D2TRA subjects receive Telitacicept combine Baricitinib
Primary Outcome Measure
Efficacy of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis [ Time Frame: maximum 1 years ]
Central Contacts
- Zhenhua Ying+86-571-3989897128
Find similar trials
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Early Rheumatoid Arthritis Lung Disease StudyRecruiting · University of Nebraska · Omaha, Nebraska
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina